![]() | Ann M DvorakDepartment of Pathology, Center for Vascular Biology Research (CVBR), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. | Department of ... |
KOL Resume for Ann M Dvorak
Year | |
---|---|
2018 | Department of Pathology, Center for Vascular Biology Research (CVBR), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. |
2017 | Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA; and. |
2016 | Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA |
2015 | Center for Vascular Biology Research and Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, USA |
2014 | Laboratory of Cellular Biology, Department of Biology, Federal University of Juiz de Fora, UFJF, Juiz de Fora, MG, Brazil (FFD,KBA,LASC,RCNM) Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (RS,PFW,RCNM) Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Boston MA 02215. |
2013 | Beth Israel Deaconess Medical Center Department of Pathology Boston MA USA Mayo Clinic Arizona, Scottsdale, AZ |
2012 | Department of Pathology, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; and Beth Israel Deaconess Medical Center, Center for Vascular Biology, Harvard Medical School, Boston, Massachusetts, USA |
2011 | Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA, . Laboratory of Immunopharmacology, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, Brazil (HD,PTB) |
2010 | Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and the Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Department of Pathology and Laboratory Medicine, Weil Cornell Medical School, New York, New York |
2009 | Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA |
2008 | Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, 02215; Department of Pathology Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA |
2007 | Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215; email: , , |
2006 | Correspondence: William C. Aird,Molecular and Vascular Medicine, Beth Israel Deaconess Medical Center, RW-663, 330 Brookline Ave, Boston, MA 02215; e-mail: waird{at}bidmc.harvard.edu. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 |
2005 | Reprints: Robert Flaumenhaft, Beth Israel Deaconess Medical Center, Center for Hemostasis, Thrombosis, and Vascular Biology Research, 41 Ave Louis Pasteur, RE319, Boston, MA 02115; e-mail: rflaumen{at}bidmc.harvard.edu. Department of Pathology/East Campus, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA |
2004 | Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; and |
2003 | Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA USA |
2002 | From the Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Department of Pathology, Beth Israel-Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215 |
2001 | Departments of Pathology (DF, AMD) and Medicine (RF, CB–M,PFW), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts From the Department of Pathology (T.P.-H., J.K., A.M.D., R.M.-E., P.C.D., M.U., J.T.J.), the Division of Infectious Diseases, Department of Internal Medicine (G.S.), the Division of Viral Pathogenesis (I.J.K., L.-A.P.), and the Department of Neurology (I.J.K., J.T.J.), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston |
2000 | Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 02215, Boston, MA, USA |
1999 | Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA |
1998 | Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 Boston, Mass. |
Ann M Dvorak: Influence Statistics
Concept | World rank |
---|---|
major intracellular pool | #1 |
hlmcs electron | #1 |
piecemeal degranulation proof | #1 |
dvorak pathol | #1 |
role lipid bodies | #1 |
household microwave ovens | #1 |
hsmc situ | #1 |
supplemented supernatants | #1 |
eosinophils humans microscopy | #1 |
stimulated samples | #1 |
charcotleyden crystals eosinophils | #1 |
cellular histamine content | #1 |
vesiculotubular networks | #1 |
ultrastructural phenotype | #1 |
cpla2 map kinases | #1 |
magnetron warmup | #1 |
differentiation partial maturation | #1 |
fibroblastcontaining cocultures | #1 |
gigo humans leukocytes | #1 |
antihuman cellubrevin | #1 |
granules elicit secretion | #1 |
cell biology basophils | #1 |
secondary granules eosinophils | #1 |
mixed granules hsmc | #1 |
20 electrondense granules | #1 |
chymase cytoplasmic vesicles | #1 |
14 patients inflammation | #1 |
platelet membrane pmd | #1 |
hagfish vwf vwf | #1 |
small macrophages microscopy | #1 |
mrna secretory granules | #1 |
criteria inhibition | #1 |
histamine stores secretion | #1 |
cpla2 lipid bodies | #1 |
situ coating surface | #1 |
anaphylactic degranulation | #1 |
caveolae capillary permeability | #1 |
vesiculotubular compartments | #1 |
biopsy samples groups | #1 |
infusion hyperosmolar solutions | #1 |
specimen containers | #1 |
granules basophils | #1 |
widespread crohn | #1 |
gold histamine | #1 |
human basophils monocyte | #1 |
presence positive cultures | #1 |
function extracellularly | #1 |
ileal stomas | #1 |
cells anaphylactic degranulation | #1 |
edematous submucosa | #1 |
Open the FULL List in Excel | |
Prominent publications by Ann M Dvorak
Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine expressed and secreted at high levels by many tumor cells of animal and human origin. As secreted by tumor cells, VPF/VEGF is a 34–42 kDa heparin-binding, dimeric, disulfide-bonded glycoprotein that acts directly on endothelial cells (EC) by way of specific receptors to activate phospholipase C and induce [Ca2+]i transients. Two high affinity VPF/VEGF receptors, both ...
Known for Vpf Vegf | Tumor Biology | Vascular Permeability Factor | Endothelial Cells | Tyrosine Kinases |
Human cord blood mononuclear cells were cultured for 35 days in media containing recombinant human interleukin 5 (rhIL-5) supplemented with a fraction of the culture supernatant of phytohemagglutinin (PHA)-stimulated human T lymphocytes from which interleukin 2 (IL-2) was eliminated. Cultured cells were studied by electron microscopy and an immunogold procedure to detect subcellular site(s) of Charcot-Leyden crystal (CLC) protein. The majority of cells (greater than 70%) developing in ...
Known for Mature Eosinophils | Clc Protein | Specific Granules | Recombinant Human | Leyden Crystal |
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
[ PUBLICATION ]
VPF/VEGF is a multifunctional cytokine that contributes to angiogenesis by both direct and indirect mechanisms. On the one hand, VPF/VEGF stimulates the ECs lining nearby microvessels to proliferate, to migrate, and to alter their pattern of gene expression. On the other hand, VPF/VEGF renders these same microvascular ECs hyperpermeable so that they spill plasma proteins into the extravascular space, leading to the clotting of extravasated fibrinogen with deposition of a fibrin gel. ...
Known for Vpf Vegf | Permeability Factor | Vascular Endothelial | Provisional Matrix | Angiogenesis New |
In contrast to normal microvessels, those that supply tumors are strikingly hyperpermeable to circulating macromolecules such as plasma proteins. This leakiness is largely attributable to a tumor-secreted cytokine, vascular permeability factor (VPF). Tracer studies have shown that macromolecules cross tumor vascular endothelium by way of a recently described cytoplasmic organelle, the vesiculo-vacuolar organelle or VVO (VVOs are grapelike clusters of interconnected, uncoated vesicles and ...
Known for Vascular Permeability Factor | Normal Venules | Electron Models | Vacuolar Organelles | Plasma Proteins |
Cytoplasmic lipid bodies of neutrophils: formation induced by cis-unsaturated fatty acids and mediated by protein kinase C.
[ PUBLICATION ]
Lipid bodies, nonmembrane-bound cytoplasmic inclusions, serve as repositories of esterified arachidonate and are increased in cells associated with inflammatory reactions. We have evaluated stimuli and mechanisms responsible for lipid body formation within human polymorphonuclear leukocytes (PMNs). Arachidonic acid and oleic acid stimulated dose-dependent formation of lipid bodies over 0.5-1 h. Other C20 and C18 fatty acids were less active and demonstrated rank orders as follows: ...
Known for Lipid Bodies | Fatty Acids | Protein Kinase | Arachidonic Acid | Unsaturated Humans |
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins
[ PUBLICATION ]
Effects of recombinant human interleukins on hematopoiesis were explored by using suspension cultures of mononuclear cells of human umbilical-cord blood and bone marrow. The results showed that interleukin 5 induced the selective differentiation and proliferation of eosinophils. After 3 weeks in culture with interleukin 5, essentially all nonadherent cells in both bone marrow and cord blood cell cultures became eosinophilic myelocytes. Culture of the same cells with interleukin 4 ...
Known for Hematopoietic Cells | Recombinant Human | Bone Marrow | Selective Differentiation | Eosinophilic Myelocytes |
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) interacts with two high-affinity tyrosine kinase receptors, VEGFR-1 and VEGFR-2, to increase microvascular permeability and induce angiogenesis. Both receptors are selectively expressed by vascular endothelial cells and are strikingly increased in tumor vessels. We used a specific antibody to localize VEGFR-2 (FLK-1, KDR) in microvascular endothelium of normal mouse kidneys and in the microvessels induced by the ...
Known for Growth Factor | Vascular Permeability | Vpf Vegf | Ultrastructural Localization | Adenoviral Vectors |
Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand.
[ PUBLICATION ]
Both human and mouse c-kit ligand induced differentiation of human mast cells in a long-term culture of the mononuclear cells of umbilical cord blood. Growth factor activity for human mast cells present in conditioned medium of BALB/3T3 fibroblasts was due to mouse c-kit ligand. Recombinant c-kit ligand induced differentiation and proliferation of mast cell progenitors in early stages of culture. However, apparent selective growth of mast cells by c-kit ligand in cord blood cell cultures ...
Known for Mast Cells | Kit Ligand | Cord Blood | Recombinant Human | Cell Differentiation |
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) is an angiogenic cytokine with potential for the treatment of tissue ischemia. To investigate the properties of the new blood vessels induced by VPF/VEGF, we injected an adenoviral vector engineered to express murine VPF/VEGF164 into several normal tissues of adult nude mice or rats. A dose-dependent angiogenic response was induced in all tissues studied but was more intense and persisted longer (months) in skin ...
Known for Angiogenic Response | Endothelial Growth | Mother Vessels | Vascular Permeability | Vpf Vegf |
Subcellular distribution of 3 functional platelet SNARE proteins: human cellubrevin, SNAP-23, and syntaxin 2
[ PUBLICATION ]
Morphologic studies have demonstrated a process by which alpha-granule contents are released from platelets. Studies aimed at defining the molecular mechanisms of this release have demonstrated that SNARE proteins are required for alpha-granule secretion. These observations raise the possibility that morphologic features of alpha-granule secretion may be influenced by the subcellular distribution of SNARE proteins in the platelet. To evaluate this possibility, we analyzed the subcellular ...
Known for Snare Proteins | Syntaxin 2 | Alphagranule Secretion | Platelet Granule | Molecular Mechanisms |
Glomeruloid bodies are a defining histological feature of glioblastoma multiforme and some other tumors and vascular malformations. Little is known about their pathogenesis. We injected a nonreplicating adenoviral vector engineered to express vascular permeability factor/vascular endothelial growth factor-164 (VPF/VEGF(164)) into the ears of athymic mice. This vector infected local cells that strongly expressed VPF/VEGF(164) mRNA for 10 to 14 days, after which expression gradually ...
Known for Vascular Endothelial | Growth Factor | Glomeruloid Bodies | Mother Vessels | Glioblastoma Multiforme |
Key People For Mast Cells
Ann M Dvorak:Expert Impact
Concepts for whichAnn M Dvorakhas direct influence:Mast cells, Lipid bodies, Human basophils, Mast cell, Electron microscopy, Ultrastructural localization, Human mast cells, Anaphylactic degranulation.
Ann M Dvorak:KOL impact
Concepts related to the work of other authors for whichfor which Ann M Dvorak has influence:Mast cells, Growth factor, Vascular endothelial, Tumor angiogenesis, Vegf expression, Breast cancer, Wound healing.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |